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engineerable hydrogel nanoparticle (NP) serves as a carrier for the optimal codelivery to tumor
cells of the chemodrug, doxorubicin (Dox) and the chemosensitizer, verapamil (Vera), aiming
at alleviating tumor MDR. The hydrogel NPs are
prepared via the copolymerization of acrylamide
and 2-carboxyethyl acrylate. Dox and Vera are
post-loaded into the respective NPs, with drug
loading around 7.7wt% and 8.0wt%, respectively.
The codelivery of Dox-NPs andVera-NPs increases
the intracellular accumulation of Dox, and
significantly enhances the cell killing ability of
Dox with respect to NCI/ADR-RES cells in vitro.
These findings suggest that such codelivery
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Chemotherapy is one of the main cancer treatment
methods. However, its efficacy is often inhibited by
multidrug resistance (MDR), a major factor behind aggres-
sive and untreatable disease patterns. MDR is classically
defined as a universal state of resilience, against a
multiplicity of drugs, including structurally and/or
functionally unrelated drugs.[1] The most characterized
mechanism of MDR is the drug efflux pump that uses
up-regulation of adenosine triphosphate (ATP)-Binding
Cassette (ABC) transporters, for example, P-glycoprotein
(P-gp).[2]Many chemotherapy drugs, including doxorubicin
(Dox), encounter drug resistance. While the drug efflux
pump effect can be overcome by increasing the dose, andthus the concentration of the drug, this may result in
unacceptable toxicity. A chemosensitizer, for example,
verapamil (Vera), can block the pathway of a drug efflux
pump and thus increase the local concentration of the drug
in the MDR tumor cell, thereby improving the therapeutic
efficacy of the drug. The combination of a chemotherapy
drug and a chemosensitizer has been found to be a good
option for the treatment of MDR.[2] However, previous
clinical trials of chemosensitizerswere not quite successful.
Thiswasattributed to their poor selectivity and lowaffinity
for P-glycoprotein, thus causing strong side effects.[2–4]
For example, a high dose of Vera may cause serious
cardiotoxicity.[5] In addition, the dosing and scheduling
adjustment of chemotherapy drug and chemosensitizer is
challenging because of varying pharmacokinetics, bio-
distribution and membrane transport considerations.[6]
Nano-drug delivery systems (nano-DDS) can prolong
the systematic circulation time of drugs, enhance their
accumulation in the diseased area, due to multivalent
targeting and the enhanced permeability and retentionDOI: 10.1002/mabi.201400035m
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thereby reducing the needed dose, and thus reducing the
drug’s side effects and enhancing the therapeutic factor.[7,8]
Nano-DDS have indeed been shown to alleviate the MDR
effect of cancer cells.[9–12] Nano-DDS may also minimize
toxicity due to size-based exclusion from certain organs.[13]
Several recent investigations have explored the codeliv-
ery of chemotherapy drugs and chemosensitizers with the
aid of various nano-DDS, including liposomes,[14–16] solid-
lipid nanoparticles,[17] micelles[18] and polymeric nano-
particles.[19,20] For example, transferrin (Tf)-conjugated
liposomes (Tf-Lip) were used for the codelivery of Dox
and Vera. Cell viability tests on Dox-resistant K562
cells, treated with Dox-Vera-Tf-Liposomes, showed 5.2
and 2.8 times greater cytotoxicity [concentration of 50%
inhibition (IC50)¼ 4.18 106 M], compared tonon-targeted
Dox-Vera-liposomes (IC50¼ 21.7 106 M) and Dox-Tf-
Liposome (IC50¼ 11.5 106 M), respectively.[15] Another
study reported the successful encapsulation of Dox and
Vera into stealth liposomes. The cytotoxicity tests on
MLLB2 rat prostate cancer cells showed that the IC50
of Dox-Vera-Liposomes is, respectively, 13 times below
that of Dox-liposomeþVera, and 2 times below that of
DoxþVera.[14]
One rational guiding this work is that of dosing
simplicity, that is, it is easier to change the mix (ratio) of
two stock NPs, one containing the drug and the other the
sensitizer only, compared to producing a series of NPs
loaded with a varying ratio of drug/sensitizer. Another is
the use of hydrogel nanoparticles, especially polyacryl-
amide nanoparticles (PAAm NPs), which have emerged as
an important drug delivery vehicle for cancer imaging and
therapy. PAAm NPs combine the advantages of hydrogel
biocompatibility and thehydrogelNP’s engineerability and
flexibility, and have enabled multifunctionality, for exam-
ple, theranostic treatment, controlled release kinetics,
stealth circulation and biodegradability.[7,21–23] Notably,
this biomaterial, polyacrylamide, has been widely used
clinically. For example, it has been used as permanent filler
(Aquamid) for facial soft-tissue augmentation for about
20 years.[24] These PAAm NPs are highly soluble in water,
and have been made controllably biodegradable;[25] they
cancarryhighpayloadsofdrugsandalsoprotect suchdrugs
from interference by enzymes in the living biological
environment, as well as contain surface ligands for the
specific targeting of cancer cells.[7] PAAm NPs (40–100nm)
have been widely used as a delivery vehicle for magnetic
resonance imaging, photodynamic therapy, tumor delin-
eation and chemotherapy.[10,22,23,25–29] For example, cis-
platin-loaded, F3 peptide-targeted PAAm NPs effectively
inhibited the growth of bothmurine ovarian tumormodels
and human tumor xenograft models, which was found
to be valid not only for cisplatin-sensitive but also for
cisplatin-resistant cell lines.[10]Macromol. Biosci. 20
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a new kind of hydrogel NP and studied its potential as a
codelivery vehicle of Dox and Vera, for overcoming MDR.
This kind of NP was prepared via the copolymerization
of acrylamide (AAm), 2-carboxyethyl acrylate (CEA) and
3-(acryloyloxy)-2-hydroxypropyl methacrylate (AHM), in a
reverse microemulsion system. The novelty of this NP
design is in its ability for adjusting the ratio of CEA/AAm
in the NP matrix, and this ratio determines the release
kinetics of Dox. Either Dox or Vera were post-loaded into
the NPs. Compared to the co-embedding of Dox and Vera
into the same batch of NPs, the loading of drugs into
separate NPs is chosen here because it facilitates dose
optimization for both in vitro and in vivo applications.
In other words, it is much easier to adjust the ratio of
Dox-NPs to Vera-NPs, compared to preparing a series of
NPs, each with a different ratio of Dox and Vera. We
studied the release kinetics of each drug from the NPs.
The NCI/ADR-RES cell line was chosen as a typical
example of a Dox-resistant cell line. The accumulation in
the NCI/ADR-RES cell line of Dox, from free Dox, Dox-NPs,
free Doxþ free Vera, and of Dox-NPsþVera-NPs, was
studied by confocal microscopy. The cytotoxicity on the
NCI/ADR-RES cell line of either free Dox, Dox-NPs, free
Doxþ free Vera, Dox-NPsþ free Vera, or of Dox-NPsþVera-
NPs, was also evaluated. The results demonstrated that
the codelivery of Dox-NPsþVera-NPs can best increase
the intracellular accumulation of Dox, as well as signifi-
cantly improve the cell-killing ability of Dox, on this
Dox resistant tumor cell line.2. Experimental Section
2.1. Materials
AAm, CEA, AHM, Vera, ammonium persulfate (APS), N,N,N0,N0-
tetramethylethylenediamine (TEMED), acrylic acid N-hydroxysuc-
cinimide ester (acrylic acid-NHS), sodium dioctyl sulfosuccinate
(AOT), Brij 30, dimethylsulfoxide (DMSO), phosphate-buffered
saline tablet (PBS), and 3-(4,5-dimethylthiazolyl-2)-2,5-diphenylte-
trazolium bromide (MTT) were purchased from Sigma Aldrich.
Ethanol (95%) and hexane were purchased from Fisher Scientific.
Doxwaspurchased fromLC laboratories.NCI/ADR-RES cell linewas
purchased fromNational Cancer Institute. Hoechst 33342, Roswell
Park Memorial Institute medium (RPMI-1640) and 0.05% Trypsin-
EDTA (ethylenediamine tetraacetate) were purchased from Invi-
trogen. Fluorescein-5-thiosemicarbazide (5-FTSC) was purchased
from Marker Gene Technologies. All the water used was purified
with a Milli-Q system from Millipore.2.2. Preparation of co(CEA-AAm) NPs
Deoxygenated hexane (45mL), AOT (1.6 g) and Brij 30 (4.3mL)were
mixed together, which was stirred vigorously to produce a14, 14, 1106–1115
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1108microemulsion. A mixture of AAm (497mg), CEA (432mg) and
AHM (428mg) was dissolved in DI water (1.3mL), which was
sonicated until dissolved completely. The monomer solution was
added into the hexane solution under argon atmosphere. After
20min, fresh APS solution (100mL, 10wt%) and TEMED (100mL)
were added into the mixture solution to initiate polymerization.
After 2 h reaction, hexane was removed by rotary evaporation.
The residue was suspended in ethanol and transferred into an
Amiconultra-filtration cell (Millipore Corp.). In order to remove the
surfactants and unreacted monomers, NPs were washed with
ethanol and DI water 5 times respectively with a 300kDa filter
membrane under a pressure of 15–20 psi. The NP solution was
lyophilized and stored in the freezer. The ratio of CEA/NPs can be
adjusted by modifying the amount of monomers added at the
beginning of the reaction.2.3. Preparation of FITC-labeled NPs
5-FTSC, acryl acid-NHS (5.6mg), AAm (497mg) and Brij 30 (0.1mL)
were dissolved in PBS buffer (1.3mL) and kept stirring overnight.
Then the solutionwasmixedwithCEA (432mg) andAHM(428mg)
and sonicated until dissolved completely. Deoxygenated hexane
(45mL), AOT (1.6 g) andBrij 30 (4.3mL)weremixed together,which
was stirred vigorously to produce a microemulsion. The monomer
solution was added into the hexane solution under an argon
atmosphere. After 20min, fresh APS solution (100mL, 10wt%) and
TEMED (100mL) were added into the mixture solution to initiate
polymerization. After 2 h reaction, hexane was removed by rotary
evaporation.The residuewas suspended inethanoland transferred
into an Amicon ultra-filtration cell (Millipore Corp.). In order to
remove the surfactants and unreacted monomers, NPs were
washed with ethanol and DI water for 5 times respectively with
a 300 kDa filter membrane under the pressure of 15–20 psi.
The NPs were lyophilized and stored in the freezer.2.4. Characterization of NPs
The size and zeta potential of NPs in aqueous solution were
measured with Delsa Nano (Beckman Coulter). Scanning electron
microscopy (SEM) images of NPs were obtained with an FEI Nova
Nanolab Dualbeam focussed ion beam workstation and scanning
electron microscope.2.5. Loading of Drugs into NPs
BothDoxandVerawere loaded intoNPsas follows: TheNP solution
in DI water (10mgmL1, 1mL) and a Dox or Vera solution in DI
water (10mgmL1, 20mL) were mixed together and kept stirring
overnight. Then the drug-loaded NP solution was centrifuged in a
centrifuge filter (100 kDa, Millipore) at 4000 g for three times, in
order to remove the unbound drug molecules. The absorbance of
Dox and Vera in NP solution was evaluated using an UV-1601 UV-
vis spectrometer (Shimadzu). The absorption wavelength of Dox
and Vera are 480nm and 280nm, respectively. The concentrations
of drugs in theNP solutionwere calculated fromBeer-Lambert Law,
while the concentration of theNP solution is known. The loadingofMacromol. Biosci. 201
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drug-loaded NPs) 100; while the encapsulation efficiency
(%)¼ (weight of drug found loaded/weight of drug input)  100.2.6. Drug Release from NPs
The release kinetics of drugs from NPs was studied under the sink
condition, since the concentration of Dox or Vera in our release
studywas 0.02mgmL1, while the solubility of Dox or Vera in PBS
was around 10mgmL1. Drug-loaded NP solution (1mgmL1,
10ml) in PBS buffer was prepared and incubated in water bath at
37 8C for release study. After incubation for 0 h, 1 h, 3h, 5h, 8 h and
24h, 1ml of Drug-NP solutionwas taken out and transferred into a
centrifuge filter (100 kDa). The NP solution was centrifuged at
4000 g for 15min at room temperature, and the filtrate was
collected forUV-visanalysis. ThefactorofDoxdegradationwasalso
considered in the release study because of the easy degradation of
Dox in PBS buffer.[30] The release profile of Dox was corrected for
degradation of Dox.2.7. Cell Culture and in Vitro Cytotoxicity Test
Human ovarian adenocarcinoma cell line NCI/ADR-RES was
cultivated in RPMI 1640 medium with 10% heat-inactivated fetal
bovine serum (Hi-FBS). In vitro cytotoxicity of drug-loadedNPswas
analyzed in NCI/ADR-RES cell line, using an MTT assay: The cells
were incubatedwithvarying formulationsofDoxon96-well plates
(5000 cells perwell) for 2 d, inwhich the final concentration of Dox
ranged from 0 to 20 103 M. After that, cells were treatedwith an
MTT reagent solution (0.83mgmL1) in colorless RPMImedium for
an additional 4 h. Then, the produced formazan crystals were
dissolved in DMSO for 1 h. The visible absorption from each well
was measured at 550nm in a Biochrom Anthos microplate reader.2.8. Confocal Microscopy Imaging
The cells were cultivated on an eight-well chambered cover glass
system (Nunc, Lab-Tek) overnight. After that, the cells were
incubated with NP solution (1mgmL1) for 6 h. Then the Hoechst
33342 dye (1mgmL1)was added into the cells and incubatedwith
cells for 30min. After incubation, unbound NPs and Hoechst dye
were removed via rinsing with fresh Dulbeccos PBS buffer three
times. The cells were incubated in colorless RPMI 1640medium for
the microscopy study, which was done with a Leica confocal
microscope (SP-5X) at the Microscopy and Image Analysis
Laboratory of the University of Michigan. The fluorescence signal
of Dox was excited at 458nm and detected over the range of 570–
700nm, while that of FITC-NPs was excited at 488nm and the
fluorescence was detected over the range of 498–530nm.
Quantitative analysis was performed by comparing the pixel
intensity of the fluorescence images using ImageJ.2.9. Statistical Analysis
Results are presented as mean standard deviation from at least
three separate experiments. The intracellular uptake and4, 14, 1106–1115
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Scheme 1. Molecular structures of acrylamide (AAm), 2-carboxy-
ethyl acrylate (CEA), and 3-(acryloyloxy)-2-hydroxypropyl meth-
acrylate (AHM).
Table 1. Size (diameter) and zeta potential of hydrogel NPs from
DLS. Data is shown as mean standard deviation.
Sample
CEA
[mol%]
Size (PBS buffer,
pH 7.4) [nm]
Zeta potential
(DI water) [mV]
#1 8 48 1 49 9
#2 25 54 1 55 3
#3 42 74 3 59 1
Dox-NPsa) 25 53 1 50 3
Vera-NPsb) 25 52 1 40 5
a)Loading of Dox/NPs: 7.7wt%; b)loading of Vera/NPs: 2wt%.
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Way Analysis of Variance (ANOVA) followed by Tukey’s multiple
comparison test using GraphPad Prism v6.00. All analyses were
performedwith a confidence interval at 95%. P-values<0.05 were
considered significant.3. Results and Discussion
3.1. Preparation and Characterization of
co(CEA-AAm) NPs
This nanoplatform was prepared by a reverse micro-
emulsion polymerization (Scheme 1), in a monomer
mixture droplet containing AAm (main matrix compo-
nent), AHM (degradable crosslinker) and CEA (monomer
providing negatively charged carboxyl groups, uniformly
throughout the NP). Cationic drugs (e.g., Dox) can be loaded
into negatively charged NPs via coulomb interaction. The
mole fraction of CEA was varied from 8% to 42% so as to
find the optimal CEA concentration that would offer high
loading, as well as slow release, of Dox. Results from
Dynamic Light Scattering (DLS) analysis showed that theFigure 1. Size distribution of hydrogel NPs from a) DLS and b) SEM i
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94.5 nm in PBS buffer (pH 7.4) (Figure 1a and Table 1). SEM
was used to observe the morphology of the dehydrated
NPs, which showed an average diameter of around 17nm
(Figure 1b). The zeta potentials of these hydrogel NPs
were around 50mV to 60mV in DI water (Table 1),
which can be attributed to the presence of the carboxyl
group in the NPs.3.2. Ion Responsive Swelling of co(CEA-AAm) NPs
We analyzed the size of NPs with varying concentration
of NaCl (from 0 to 1M) using DLS (Figure 2), with NPs
containing 25% CEA chosen as example. The results
showed that the NP size decreased from 108nm to 53nm
when NaCl concentration in buffer was increased from
0M to 0.100M. Further increase in NaCl concentration
from 0.100M to 1M has no significant impact on the size.
These results demonstrate that the NP size was ion
concentration-dependent in the range of 0M to 0.100M.
In contrast, the size of PAAm NPs (without any carboxyl
group) was stable under varying ion concentrations in
the same buffer.
This swelling behaviour is due to the COO– groups in the
NPs, which are bound to the matrix and cannot diffusemage.
14, 14, 1106–1115
bH & Co. KGaA, Weinoutside. The counter ions (e.g., Naþ, Ca2þ),
remain confined inside the NPs, to
maintain electrical neutrality. Thus the
total mobile ion concentration inside the
NPs exceeds that of the external solution
under lower ion concentration in solu-
tion. This causes an osmotic pressure
difference and leads to increased water
retention. This may be a reason for the
NPs to swell in solution with lower ionic
strength, and to shrink on increasing the
ionic strength. Thus the size of the NP,
which is related to the osmotic pressure,
depends on the difference between theheim 1109
Figure 2. Diameter of hydrogel NPs (from DLS) vs NaCl
concentration in DI water. Error bars indicate the standard
deviations.
Figure 3. Degradation of Dox in Dox solution and Dox-loaded NP
solution in PBS buffer at 37 8C. Dox concentration: 20mgmg1;
Dox/NPs: 2wt%. Error bars indicate the standard deviations.
www.mbs-journal.de
M. Qin, Y.-E. K. Lee, A. Ray, R. Kopelman
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solution.[31]3.3. Loading of Drugs into NPs
We loaded Dox and Vera into co(CEA-AAm) NPs via post-
loading, inwhich the CEA/NPsmolar ratiowas 8%, 25% and
42%. Dox and Vera were separately loaded into two sets of
NPs. The loadingofDoxandVera in theNPswasdetermined
to be 7.7wt% and 8.0wt% respectively, while the encapsu-
lation efficiency was 81% and 80% respectively. DLS
analysis results (Table 1) showed that the hydrodynamic
size of Dox-NPs and Vera-NPs were 53 1nm and
52 1nm, respectively, which is similar to the size of
blankNPs (54 1nm).After drug loading, the zetapotential
of the NPs changed from 55 3mV to 50 3mV (Dox-
NPs) and 40 5mV (Vera-NPs) respectively, probably
due to partial neutralization of the surface charge on the
NPs by the Dox and Vera. Additionally we were also able
to efficiently incorporate methylene blue, a positively
charged photosensitizer, into the co(CEA-AAm) NPs by post
loading (data not shown). These results suggested that the
co(CEA-AAm) NPs can be used as a high-capacity drug
delivery vehicle for cationic drugs. The loading of drugs into
NPs can be attributed to non-covalent bonding, especially
the strong electrostatic interaction between the anionic
NPs and the cationic drug molecules.3.4. Degradation of Dox in Dox Solution vs Dox-NP
Solution
Dox easily degrades in PBS buffer at body temperature. We
compared the chemical degradation of Dox in free Dox
solution and inDox-NP solution. Figure 3 shows that 37%of
Dox in free Dox solution degraded at 37 8C, in PBS buffer,
within 24h. Over the same time period, only 6% of Dox in
the Dox-NP solution degraded (Figure 3). These resultsMacromol. Biosci. 201
 2014 WILEY-VCH Verlag GmbHindicate that our NPs can effectively slow down the
degradation of Dox. Our results are analogous to results
from a related publication,[32] which demonstrated that
the encapsulation of Dox into polymeric NPs, composed of
poly(ethylene glycol) and poloxamer 407 (Pluronic F127),
lengthened the lifetime of Dox from 50h to 173h in
PBS buffer. This protective effect can be related to the
encapsulation of Dox into the hydrophobic domains of the
NPs, reducing the contact of Dox with the hydrophilic
environment, which may induce a keto/enol tautomeriza-
tion and deprotonation of Dox.[33]3.5. Release Kinetics of Dox and Vera from NPs
The drug release profile from the NP matrix significantly
affects its therapeutic efficacy. We studied the release
kinetics of Dox from NPs in which the molar ratio of CEA
was fixed at 8%, 25% and 42%. The loading of Dox/NPs
was kept at 2wt%. For analysis of the release study results,
the degradation of Dox in PBS buffer was taken into
account, using Figure 3 as the calibration curve. It was
found that around 20% of Dox was released within 24h
from NPs with 42% CEA; whereas over the same period,
around 40% of Dox was released from NPs with 8% CEA
(Figure 4a). This shows that the release kinetics of Dox
from NPs can be adjusted by the NP matrix composition,
that is, the mole fraction of CEA. We also studied the
release kinetics of Vera fromNPs over 24h, and the loading
of Vera/NPs was kept at 2% wt as well. The molar ratio of
CEA in theseNPswasfixed at 8%, 25%, and42%.Around60–
70% of Vera was released over 24h from each of the
NPs (Figure 4b), demonstrating that the release profile of
Vera did not depend on the mole fraction of CEA in the
NP matrix.
The release kinetics of drugs fromNPs are affected by the
property of the matrix and the solubility of the drug in
solution. We believe that the release of Dox from NPs is a4, 14, 1106–1115
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Figure 4. Releasing behaviours of a) Dox and b) Vera from hydrogel NPs with varying ratio of CEA in NP matrix. Dox/NPs: 2wt%; Vera/NPs:
2wt%; NP concentration: 1 mg mL1. Error bars indicate the standard deviations.
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the NP matrix containing 42% CEA is stronger than that
with the NP matrix containing 8% CEA (more negatively
charged as indicated by zeta potential data), causing slower
release ofDox fromNPswithhigher ratios of CEA.However,
the release kinetics of Vera from the NPs is independent of
the ratio of CEA/NPs, whichmay be relatedwith the higher
hydrophilicity of Vera.3.6. Accumulation of Free Dox, Dox-NPs,
Free Doxþ Free Vera and Dox-NPsþVera-NPs in
NCI/ADR-RES Cells
We studied the accumulation of free Dox, Dox-NPs, free
Doxþ free Vera and Dox-NPsþVera-NPs in cells, using
confocal microscopy.[11,34] The human ovarian adenocarci-
noma cell line NCI/ADR-RES was chosen because of its
reported resistance to Dox.[35] The distribution of Dox in
cells was monitored via its own fluorescence signal (red in
Figure 5). The cell nucleus was labelled with the Hoechst
dyes (blue). Cells were incubated with different formula-
tions of Dox for 6 h. After incubation, unbound drug or NPs
were removed by washing with PBS buffer for three times.
Our results (Figure 5a) show that, after incubationwith free
Dox for 6h, the Dox signal (red) is detected in the NCI/ADR-
RES cells, showingmoderate uptake of Dox into these cells.
After incubation with Dox-NPs for 6 h, the intensity of Dox
in cells is marginally but not significantly less than that in
those cells after incubation with free Dox. After incubation
with free Doxþ free Vera for 6 h, the signal intensity of Dox
in cells was almost six times higher than the fluorescence
intensity from cells with just free Dox (p< 0.05); after
incubation with Dox-NPsþVera-NPs for the same incuba-
tion time, the Dox signal in cells was almost seven times
higher than the intensity in cells after incubationwith just
free Dox (Figure 5b, p< 0.05). The overlap of fluorescence
signals from Dox and Hoechst dye (purple in Figure 5a)
demonstrated that a large amount of Dox accumulated inMacromol. Biosci. 20
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These results demonstrated that Dox-NPsmay not increase
theuptakeofDox into tumorcells, compared touptake from
freeDox solution. Similar resultswere foundwithpolymer-
lipid hybrid nanoparticles (PLN), which cannot increase
the uptake of Dox significantly by MDA435/LCC6/MDR1
human breast cancer cells after 4 h of incubation.[17]
However, most importantly, we found that the formula-
tions of free Doxþ free Vera and Dox-NPsþVera-NPs did
significantly improve the uptake of Dox in these drug-
resistant cells. This confirms that Vera or Vera-NPs, as a
chemosensitizer, can inhibit the drug efflux pump and
increase the local concentration of Dox in these MDR cells
(Scheme 2).[36]3.7. Colocalization of Dox and FITC-NPs in
NCI/ADR-RES Cells
We also studied the colocalization of Dox molecules
and carrier NPs in NCI/ADR-RES cells, via confocal
microscopy. In order to track their signal, the NPs were
labelled with FITC. Cells were incubated with Dox-FITC-
NPs and Vera-FITC-NPs for 6 h. As mentioned previously,
the Vera-NPs significantly improved the accumulation
of Dox in cells. We observed strong fluorescence signals
from Dox (red) and the FITC-NP (green), present in the
cells (Figure 6a). The green signal from the FITC-NPs
inside the cells demonstrates the successful uptake of
these NPs into the cells (Figure 6b). However, we also
note that the majority of the FITC signal was found on
the cell membranes (Figure 6b), indicating that large
amounts of NPs may stay attached to the cell membrane.
The overlap of the fluorescence signals from Dox and
from FITC-NPs in cells is shown in Figure 6c. The
colocalization of Dox and FITC-NPs (orange) was found
in certain locations in the cells, which may be the location
of the Dox-loaded NPs, or of the Dox just released from
the NPs. In addition, a strong Dox signal (red) was also14, 14, 1106–1115
mbH & Co. KGaA, Weinheim 1111
Figure 5. a) Confocal microscopy images of NCI/ADR-RES cells after incubation with free Dox, Dox-NPs, free Doxþ free Vera and Dox-
NPsþVera-NPs for 6 h. The nucleus is stained with the Hoechst dye (blue). Top: fluorescence signals from Dox (red); bottom: overlap of the
fluorescence signals from Dox (red) and Hoechst dye (blue). b) Histogram analysis of pixel intensity of Dox in (a). Dox concentration:
5 106 M; Vera concentration: 5 106 M; scale bar: 25mm. Error bars indicate the standard deviations.  p<0.05, in comparison to Dox; #
p<0.05, in comparison to Dox-NPs and DoxþVera.
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1112found in other locations inside the cells, showing the
intracellular distribution of the Dox that was released
from the NPs and delivered into the cells. These results
demonstrate that co(CEA-AAm) NPs can be taken up byScheme 2. Delivery into drug-resistant tumor cells of both
doxorubicin (derails DNA) and verapamil (blocks efflux pump)
with hydrogel NPs.
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which is important for functionof theNPs, that is, servingas
a drug delivery vehicle.3.8. In Vitro Cytotoxicity on NCI/ADR-RES Cells of
Free Dox, Dox-NPs, Free Doxþ Free Vera, Dox-
NPsþ Free Vera and Dox-NPsþVera-NPs
The cytotoxicity of several formulations of Dox on
NCI/ADR-RES cells (Dox-resistant cell line) was studied in
vitro using MTT assay. Additionally, we also tested the
cytotoxicity of blank NPs and free Vera on the same cell
line. The concentration of Vera (5 106 M) was chosen
following previous literature.[37] Our results (Figure 7)
show that over 90% ( 7%) of the cells survived after
incubation with blank NPs (1mgmL1) for 2 d, while
around 98% ( 8%) of the cells survived after incubation
with free Vera (5 106 M) for 2 d, demonstrating
that neither blank NPs nor Vera show significant toxicity
to NCI/ADR-RES cells. Then we tested the cytotoxicity of
freeDox,Dox-NPs, freeDoxþ freeVera,Dox-NPsþ freeVera4, 14, 1106–1115
& Co. KGaA, Weinheim www.MaterialsViews.com
Figure 6. Confocal microscopy images of NCI/ADR-RES cells after 6h incubation with Dox-loaded FITC-NPs and Vera-loaded FITC-NPs. a)
Fluorescence signal from Dox (red) in the cells; b) fluorescence signal from FITC-NPs (green) in the cells; c) overlap of the fluorescence signal
(orange) from Dox and FITC-NPs. Incubation time: 6 h; NP concentration: 1mgmL1; scale bar: 25mm.
Overcoming Cancer Multidrug Resistance by Codelivery . . .
www.mbs-journal.deand Dox-NPsþVera-NPs on the same cell line. Our results
(Figure 8 andTable 2) showed that the estimated IC50 of free
Dox on NCI/ADR-RES cells was higher than 20 106 M,
more than 250 times higher than that on rat gliosarcoma
cell line 9L cells (0.07 106 M), confirming that the NCI/
ADR-RES cell line is indeed resistant to Dox. The addition of
free Vera reduced the IC50 of Dox to 10 106 M (p< 0.05),
which demonstrated that Vera improved the cell killing
ability of Dox on this drug-resistant cell line, correlating
well with its ability to improve the intracellular accumula-
tion of Dox (see above). The IC50 of Dox-NPs was around
19 106 M, which shows that Dox-NPs have marginally
better cell-killing efficiency, compared to free Dox. The IC50
ofDox-NPsþVera-NPswas foundtobearound2.5 106 M,
which is 8 times lower than that of the free Dox alone
(p< 0.05), 4 times lower than that of free Doxþ free Vera
(p< 0.05) and marginally but not significantly lower than
that of the Dox-NPsþ free Vera combination. Notably, the
highest concentration of NPs for Dox-NPsþVera-NPs in
Figure 8 was 0.23mgmL1, while our previous results
(Figure 7) showed that blank NPs were not toxic to cells,
even at 1mgmL1. Therefore, we believe that the
cytotoxicity of Dox-NPsþVera-NPs (Figure 8) is not due
to toxicity of the NP carriers.Figure 7. Viability of NCI/ADR-RES cells after incubation with
blank NPs (1mgmL1) and Vera (5 106 M) for 2 d. Error bars
indicate the standard deviations.
Macromol. Biosci. 20
 2014 WILEY-VCH Verlag Gmwww.MaterialsViews.comThe enhanced cell-killing ability of Dox-NPsþVera-NPs
can be attributed to the incorporation of the chemo-
sensitizer (Vera), as well as to the protective effect of the
nanoplatform on the Dox. In addition, the NPs may also
partially protect Vera from being metabolised, which is
mediatedbycytochromeP450enzymes in theNCI/ADR-RES
cell line. It has been reported that Vera is subject to an
extensive oxidative metabolism mediated by cytochrome
P450 enzymes in the body.[38] Indeed, the expression of
cytochrome P450 has been observed in the NCI/ADR-RES
cell line.[39] Additionally, the encapsulationofVera intoNPs
may largely obviate, in vivo, its potential for severe cardiac
side effects.[5] This is due to the enhanced accumulation of
such Vera-containing NPs into tumors via the EPR effect,
and potentially by targeting.[29] In contrast, the much
tighter cardiac endothelial walls may prevent any signifi-
cant local Vera-NP accumulation, as they have been
reported to exclude NPs larger than 6nm.[13] Thus the use
of hydrogel NPs for sensitizer delivery is expected to avoid
sensitizer toxicity, while overcoming the MDR effect.Figure 8. Viability of NCI/ADR-RES cells after incubation for 2 d
with free Dox, Dox-NPs, free Doxþ free Vera, Dox-NPsþ free Vera
and Dox-NPsþVera-NPs. Dox/NPs: 7.7wt%; Vera/NPs: 2wt%;
Vera concentration: 5 106 M. Error bars indicate the standard
deviations of seven separate experiments.  p<0.05, in
comparison to Dox;  p<0.05, in comparison to Dox-NPs; #
p<0.05, in comparison to Dox-NPs and DoxþVera.
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Table 2. IC50 value of Dox in the formulation of free Dox, Dox-NPs, free Doxþ free Vera, Dox-NPsþ free Vera and Dox-NPsþVera-NPs. IC50
of Dox is the concentration of Dox required to cause 50% cell killing.
Estimated IC50 of Dox
[ 106 M] Dox Dox-NPs DoxþVera Dox-NPsþVera Dox-NPsþVera-NPs
NCI/ADR-RES >20 19 10 4.5 2.5
www.mbs-journal.de
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11144. Conclusion
With the aim of overcoming MDR, we successfully
developed a codelivery system of Dox (chemodrug) and
Vera (chemosensitizer) using hydrogel NPs. These hydrogel
NPs were prepared via copolymerization of AAm, CEA and
AHM, with a varying amount of CEA towards optimized
delivery kinetics. We observed that the NP size was ion-
concentration dependent. The NP matrix enhances the
stability of Dox, and the NP size promises to minimize the
cardio-toxicity of Vera, as well as potential Dox toxicity to
other organs. These NPs also have a high potential for
flexible engineerability, including future specific targeting
to the tumor. With this nanoplatform, high loading and
slow release of both Dox and Vera have been achieved
successfully. The release kinetics of Dox from the NPs is
adjustable, based on the ratio of carboxyl groups per NP.
This nanoplatform also protects Dox from degradation.
Notably, these NP combinations were well incorporated
by the Dox-resistant cell line (NCI/ADR-RES), thus behav-
ing as an efficient delivery vehicle for Dox. Moreover,
with the aid of free Vera and especially Vera-NPs, the
intracellular Dox concentration can be significantly
increased, demonstrating the advantage of such a synergis-
tic delivery approach for drug resistant cells. Most
importantly, the codelivery of Dox-NPsþVera-NPs did
show a synergistic killing effect on these drug-resistant
cells. The IC50ofDox-NPsþVera-NPswas8 times lower than
that of free Dox alone, or Dox-NPs, and 4 times lower than
that of free Doxþ free Vera. Thus the codelivery nano-
platform increased the drug efficacy and will potentially
minimize toxicity, of both chemodrug and chemosensitizer
(due to tumor targeting and size of NP, protecting from
cardio-toxicity). It offers a promising nanomedicine ap-
proach to drug resistant tumor therapy, and thus should
undergo further in vivo studies.Acknowledgements: The authors thank Teppei Shirakura for
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